The relapse risk of AML patients undergoing autologous transplantation correlates with the stem cell mobilizing potential

Leuk Res. 2012 Nov;36(11):1325-9. doi: 10.1016/j.leukres.2012.05.027. Epub 2012 Jun 23.

Abstract

Autologous stem cell transplantation (ASCT) is widely used to consolidate first remission in AML. We determined the significance of circulating CD34+ cells at the day of blood stem cell collection in 78 AML patients. Patients mobilizing more than 60,000 CD34+ cells/ml had shorter overall survival (OS; P=0.0274), shorter time to progression (TTP; P=0.0014), and a higher relapse rate (P=0.0177). High levels of CD34+ cells were an independent marker for shorter OS and TTP in a multivariate analysis. These data suggest that ASCT is associated with unfavorable outcome in AML patients with high levels of mobilized peripheral CD34+ cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antigens, CD34
  • Female
  • Hematopoietic Stem Cell Mobilization / methods*
  • Humans
  • Kaplan-Meier Estimate
  • Leukemia, Myeloid, Acute / mortality
  • Leukemia, Myeloid, Acute / surgery*
  • Male
  • Middle Aged
  • Peripheral Blood Stem Cell Transplantation / methods*
  • Peripheral Blood Stem Cell Transplantation / mortality*
  • Prognosis
  • Proportional Hazards Models
  • Recurrence
  • Retrospective Studies
  • Risk Factors
  • Transplantation, Autologous / methods
  • Transplantation, Autologous / mortality
  • Young Adult

Substances

  • Antigens, CD34